Clinical features: Measles is a serious respiratory infection. It is characterized by prodrome fever (up to 105 ° F) as well as malaise, cough, coryza, and conjunctivitis - three “C” -, pathognomonic patches (Koplik spots) followed by the icon maculopapular rashexternal. The rash usually appears about 14 days after exposure. The rash spreads from the head to the trunk to the lower extremities. Patients are considered infectious diseases from 4 days before 4 days after the onset of the rash. Significantly, sometimes immunocompromised patients do not have a rash. Complications: Common complications of measles include otitis media, bronchopneumonia, laryngotracheobronchitis, and diarrhea. Even in healthy children before, measles can cause serious illness that requires hospitalization. One in 1,000 people with measles will have acute encephalitis, which often results in permanent brain damage. One in three children out of every 1,000 infected with measles will die from respiratory and neurological problems. The external iconic Subacute sclerosing panencephalitis (SSPE) is a rare, but fatal debilitating neurological disorder characterized by deteriorating behavioral and cognitive impairment and seizures that usually occur 7 to 10 years after a measles infection. People at high risk of complications: People at high risk of serious illness and measles problems include: Newborns less than 5 years of age, adults over the age of 20, pregnant women, people with compromised immune systems, such as leukemia and HIV infection. Transmission: Measles is one of the most contagious diseases; Up to 9 out of 10 people who are easily infected close to a measles patient will develop measles. The virus is transmitted through direct contact with infectious droplets or airborne pathogens when an infected person breathes, coughs, or sneezes. The measles virus can remain airborne for up to two hours after the infected person has left the area. Laboratory and diagnostic tests: Health care providers should consider measles in patients with fever and clinical symptoms associated with measles, especially if the person has recently traveled internationally or has been exposed to a person with febrile rash. Healthcare providers are required to report suspected measles cases to the local health department. Laboratory verification is important for all rare measles cases and all outbreaks. IgM antibody antibody detection in serum and measles RNA by real-time polymerase chain reaction (RT-PCR) in the respiratory model are the most common ways to confirm measles infection. Healthcare providers should receive both a serum sample and a throat swab (or nasopharyngeal swab) from patients suspected of having measles when they first come in contact with them. Urine samples may also contain the virus, and if possible, collecting both respiratory and urine samples may increase the chances of contracting the measles virus. Cellular analysis can also be performed to determine the type of measles virus. Genotyping is used to design methods for transmitting measles virus. Genetic data can help link or remove linking cases and can raise the source of imported cases. Genotyping is the only way to differentiate between wild-type measles virus and outbreaks caused by recent measles vaccinations. Vaccination: Measles can be prevented with a measles vaccine, which is widely used as a combination vaccine for measles-mumps-rubella (MMR). The measles-mumps vaccine-rubella-varicella (MMRV) vaccine can be used in children aged 12 to 12 months to protect against measles, mumps, rubella and varicella. A measles vaccine with one antigen is not available. One dose of MMR vaccine is approximately 93% effective in measles prevention; two doses are approximately 97% effective. Almost anyone who does not respond to the measles portion of the first dose of MMR vaccine aged 12 months or older will respond to the second dose. Therefore, a second dose of MMR is given to deal with primary immunization failure. Vaccine recommendations: Children: The CDC recommends standard childhood immunizations for the MMR vaccine starting with the first dose at 12 to 15 years of age, and the second dose at 4 to 6 years or at least 28 days following the first dose. The measles-mumps-rubella-varicella (MMRV) vaccine is available for children from 12 months to 12 years of age; the minimum time between doses is three months. Students in post-secondary education institutions: Post-secondary school students without proof of measles vaccine require two doses of the MMR vaccine, the second dose being given no later than 28 days after the first dose. Adults: People born in 1957 or later who have no evidence of measles vaccination should receive at least one dose of the MMR vaccine. International travelers: People 6 months or older who will be traveling internationally should be protected from measles. Before international travel infants 6 to 11 months of age should receive a single dose of the MMR vaccine. Babies 12 months or older should have dosage of 2 doses of the MMR vaccine (the first dose of the MMR vaccine should be given if they are 12 months or older; the second dose is within 28 days after the first dosage). Adolescents and adults born during or after 1957 without evidence of measles protection should have dual dosage of the MMR vaccine, a second dose given within 28 days after the first dose. Infants who receive one dose of the MMR vaccine before their first birth should receive two additional doses according to the usual recommended schedule (one dose at 12 to 15 months of age and one dose at 4 to 6 years of age or at least 4 days). The measles-mumps-rubella-varicella (MMRV) vaccine is also available for children from 12 months to 12 years. If used in place of the MMR vaccine, the first dose should be given 12 months or more, and the second dose within three months after the first dose. MMRV should not be given to anyone older than 12 years.
You must be logged in to post a comment.